IDM Pharma, Inc. Announces Acceptance For Review Of The NDA For Junovan(TM) (Mifamurtide)
IRVINE, Calif.--(BUSINESS WIRE)--IDM Pharma, Inc. (NASDAQ:IDMI) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review IDM’s New Drug Application (NDA) for Junovan™ (mifamurtide for injection). Junovan is intended for use in the treatment of patients with newly diagnosed resectable high grade osteosarcoma following surgical resection in combination with multiple agent chemotherapy.